Rezolute presents hyperinsulinism data at Endocrine Society meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- Matador Resources to acquire Paloma Permian for $1.275B
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
June 17, 2026 7:00 AM EDTPresentations included analyses of natural history and adverse outcomes in congenital hyperinsulinism (HI), as well as previously reported results from the Companys Phase 3 sunRIZE study in congenital HI and a case series from its Expanded Access Program (EAP) in tumor HI
REDWOOD CITY, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today highlighted four data presentations delivered at the Annual Meeting of the Endocrine... More
